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INTRODUCTION. At present, only eight men with loss-of-function mutations in the
CYP19A1 gene have been described (1). We report the genetic study of four adult men
with undetectable serum estrogens, unfused epiphyses, eunuchoid skeletal proportions,
continuing linear growth, tall stature, genu valgum, osteoporosis, obesity and achantosis
nigricans. Patient 1 (26-yrs/182cm) and 2 (28-yrs/187cm) are from Turkey, Patient 3 (44-
yrs/185cm) and 4 (29-yrs/197cm) are two brothers from Jordan. All patients had a history
of consanguinity (father and mother of each patient are cousins).
METHODS. All coding exons with their flanking intronic sequences of CYP19A1 gene,
amplified by PCR, were sequenced by ABI-Prism 3130 Genetic Analyzer and compared
with known human CYP19A1 gene sequences.
RESULTS. Patient 1 was homozygous for a point mutation in the first nucleotide of intron
3 (IVS3+1G>T); Patient 2 homozygous for a G>A mutation (c.1124 G>A) in exon IX
resulting in protein missense mutation p.R375H. The two brothers (Patients 3 and 4) had
a homozygous mutation in exon IV (c.434 G>A) leading to Arg to Gln substitution at
position 115 (p.R115Q). All patients had impaired glucose tolerance, Patient 3 was
diabetic, Patient 2 had a history of three forearm bone fractures after minimal trauma,
Patient 1, 3, and 4 had impaired liver function. Patient 1 had documented GH-deficiency,
all other patients had no evidence of GH hypersecretion.
CONCLUSIONS. The description of these new four aromatase-deficient men confirms the
detrimental effects of congenital estrogen deficiency on glucose, liver and bone
metabolism (particularly bone maturation and mineralization) (1). The homozygous
missense mutation in exon IV (p.R115Q) (Patients 3 and 4) is novel: both aminoacids are
basic, their different conformational structure probably leads to tertiary or quaternary
distortion in protein structure. The other two known mutations are found in homozygosis
for the first time. Clinical evidence of osteoporotic fractures is described for the first time
and further emphasizes estrogen role on bone health in men and the need for fracture
prevention in these patients (2). Thus, drugs preventing bone fractures could be
considered as additional treatment other than estrogen replacement (3). Finally, tall
stature with concomitant GH-deficiency or with low to normal GH secretion depends on
unfused epiphyses that allows bone elongation resulting in eunuchoid skeletal proportions
(4).
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